Navigation Links
First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers

Two compounds that zero in on cancer cells spreading throughout the body, while ignoring primary tumor cells, could someday give doctors a whole new weapon in the fight against tough-to-treat metastatic disease, according to Weill Medical College of Cornell University researchers.

The compounds, called synthetic migrastatin analogues, prevented 91 to 99 percent of metastatic breast cancer cells in mice, and are the first to target only metastatic cells.

"They're unbelievably effective, and in vitro study suggests they'll work just as well at inhibiting the migration of prostate and colon cancer cells," said senior researcher Dr. Xin-Yun Huang, Professor of Physiology and Biophysics at Weill Cornell Medical College in New York City.

The findings have just been published in Proceedings of the National Academy of Sciences.

For decades, doctors have fought cancer by using surgery, chemotherapy, or radiation to excise or shrink the primary tumor.

"However, in too many cases it's simply impossible to completely remove the tumor," Dr. Huang explained. "So recently the idea of targeting cell migration -- metastasis -- has become an alternative strategy that's gained a lot of interest among researchers."

If compounds could be found that slowed or halted cancer spread, doctors could gain valuable time in shrinking the primary tumor. "If we had the luxury of time, we could treat that primary tumor at lower doses, too, with fewer side effects for the patient," Dr. Huang said.

Until now, agents that specifically target metastatic cells have remained elusive. However, a new avenue of research opened up when Dr. Huang's team noticed that the Streptomyces bacterium -- the bug that gives us the antibiotic streptomycin -- also produces a natural compound called migrastatin, which appears to inhibit cell migration.

Natural migrastatin's effect is relatively weak, but Dr. Huang suspected the molecule might be manipulated in
'"/>

Source:Cornell University


Page: 1 2 3

Related biology news :

1. First-ever genomic test predicts which lung cancer patients need chemotherapy to live
2. Compounds in plastic packaging act as environmental estrogens altering breast genes
3. Novel Enzyme Shows Potential As An Anti-HIV Target
4. Potential Drug Target For Treating Cocaine Abuse Found
5. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
6. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
7. New Therapeutic Target Identified In Inherited Brain Tumor Disorder
8. Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates
9. Targeted virus compels cancer cells to eat themselves
10. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
11. Targeting tumors the natural way

Post Your Comments:
(Date:11/9/2009)...ADELPHIA, NOVEMBER 9, 2009 A nutritionist whose ...etables to the federal Women, Infants and Children...s Agnes Higgins Award for outstanding achievement ...il Harrison, Ph.D., MNS, , a professor in the Depa...ity of California, Los Angeles School of Public He...
(Date:11/8/2009)...HEALTH EDUCATION DESIGNED FOR ADULTS WITH INTELLEC...VES , An Indiana University study involving adu...adults increased their personal health knowledge a..., Adults with ID, an internationally accepted ter...es of obesity, physical inactivity and preventable...
(Date:11/6/2009)...-dwelling ants generally live in harmony with thei...hen they run out of space in their trees of choice...s. , The research, published in the November iss...ocument that ants bore into live trees, and it reo...tween ants and plants. , Ants and certain specie...
Breaking Biology News(10 mins):March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 3Ants are friendly to some trees, but not others 2Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal 28R 29 Solution and Announcement of Lawsuit by Sepracor UCB 49926 1Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal 28R 29 Solution and Announcement of Lawsuit by Sepracor UCB 49926 2Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal 28R 29 Solution and Announcement of Lawsuit by Sepracor UCB 49926 3Conceive Introduces New MyConceive Online Community for Women Seeking to Get Pregnant 49921 1Conceive Introduces New MyConceive Online Community for Women Seeking to Get Pregnant 49921 2Preclinical Proof of Concept Studies Published for Novavax Seasonal Influenza Virus Like Particle Vaccine 12765 1Preclinical Proof of Concept Studies Published for Novavax Seasonal Influenza Virus Like Particle Vaccine 12765 2Preclinical Proof of Concept Studies Published for Novavax Seasonal Influenza Virus Like Particle Vaccine 12765 3Preclinical Proof of Concept Studies Published for Novavax Seasonal Influenza Virus Like Particle Vaccine 12765 4
... in German . , DNA, the molecule that acts as ... life, is highly resistant against alteration by u...for its photostability presents some puzzling prob...four chemical bases that make up the DNA molecule....showing that DNA strands differ in their light sen...
...tion to the IOF World Congress on Osteoporosis 200...until October 31, 2008. , To benefit from lower ...www.iofbonehealth.org/wco/2008/homepage.html . Sp...ants from non-OECD countries and for IOF members. ...at higher rates, will be possible. , Your chance...
..., Inc. (Nasdaq:,AWRE), a leading supplier of broad...led a conference call to discuss the company,s ope...ursday, October 23, 2008, at 5:00 p.m.,Eastern Tim...st the,earnings conference call., This call is be...Investor Relations page of our website at http://...
Other Biology News:Can genetic information be controlled by light? 2Aware Announces Q3 2008 Earnings Conference Call 2
(Date:11/8/2009)...ovember 6, 2009 As global temperatures and energy...gy will be key to a sustainable future. An attra...two studies published online in Genome Research ...enome structures of bioethanol-producing microorga...cal in developing new technologies needed to imple...
(Date:11/6/2009)..., LYNBROOK, N.Y., Nov. 6 /PRNewswire-FirstCall/ -..., a biopharmaceutical company developing first-in-...its financial results for the third quarter ended ...y that, in September of this year, the FDA,s Arthr...y a vote of 12-0, the approval of XIAFLEX(TM) for ...
(Date:11/6/2009)..., SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCall...Completed transfer of Qutenza(TM) E.U. Marketing A... significant progress in commercial readiness acti...es; Senior Director, Marketing; and Director, Comm...o board as director and Audit Committee chairman ...
(Date:11/6/2009)... The agenda for Arrowhead&rs...erence, which is set to take place on February 22-...his three day conference we will highlight key iss...eakers to share their experiences. , ...09 -- The agenda for Arrowhead’s 2010 Perso...
Breaking Biology Technology:Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3
...XEL International Corporation (Nasdaq: PRXL ), a...r, will address important industry issues at the D...Meeting, being held from March 23 - 25, 2009 in Be...rs will present on topics ranging from global bios...mbination products, and clinical process validatio...
...stCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:...results for the fourth quarter and year ended Dece...les results in our Medical Products Business and w... new technology initiatives despite a challenging ...t and CEO of Angiotech. "Not only did we increase ...
...nd AMSTERDAM, March 5 ,Agendia, a world leader in ...appointment of Dr. Albert A. (Al) Luderer to its S...30 years of experience in in vitro medical,diagnos...ent. Currently, he,is the Chief Executive Officer ...y using innovative platform technologies to dramat...
Other Biology Technology:PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 2PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 3PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 4PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 28Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board 2
AC1 Auto System, BioChemi™ Camera from UVP
Rabbit Anti-Pendrin (H-195) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
GeneAmp AccuRT RNA PCR Kit with Controls from Applied Biosystems
Mouse Anti-Human HLA-DRbeta Monoclonal Antibody, Unconjugated, Clone DA2 from Santa Cruz Biotechnology, Inc.
Biology Products: